In an environment of inflated list prices for prescription drugs, in the United States, payers and patients rely upon significant negotiated discounts in order to afford and access medicines. These discounts are primarily achieved through the work of pharmacy benefit managers (PBMs). This report examines how traditional PBM pricing models for commercial plan sponsors compares to the published prices of Mark Cuban Cost Plus Drug Company.
Read More